News

DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke
DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
DiaMedica Therapeutics Announces the Early Exercise of Warrants from Strategic Investor
DiaMedica Announces the Initiation of Phase 2 Trial Evaluating DM199 (Recombinant Human KLK1) in Patients with Acute Ischemic Stroke
DiaMedica Announces Recently Granted Formulation Patent in U.S. for DM199
DiaMedica Announces Dr. Nancy Chang to its Strategic Advisory Board
DiaMedica Therapeutics Completes Private Placement With U.S. Based Family Office
DiaMedica Announces Issuance of European Composition of Matter Patent and Additional Worldwide Filings for DM199
DiaMedica Presents Updated Positive DM199 Phase Ib Trial Identifying A Superior Subcutaneous Delivery Profile